- Merrimack Pharmaceuticals' (MACK) MM-121 misses its PFS primary endpoint in a Phase 2 trial evaluating the treatment in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers.
- Hazard Ratio was 1.
- The company says "ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a potential subpopulation of patients benefiting from MM-121 treatment in combination with paclitaxel."
- In the group receiving the combination therapy, there was "an overall increase in all grades of gastrointestinal toxicities." (PR)
- MACK -12% premarket.
From other sites
at Zacks.com (Feb 27, 2015)
at Zacks.com (Feb 26, 2015)
at Zacks.com (Feb 24, 2015)
at Benzinga.com (Jan 13, 2015)
at Nasdaq.com (Dec 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs